A recent study published in European Urology Focus reports that the neutrophil-lymphocyte ratio (NLR) in the blood before surgery may be used as a biomarker to predict survival following cytoreductive nephrectomy plus removal of the tumour blood clot (thrombectomy) for renal cell carcinoma (RCC).

The study involved 332 patients with metastatic RCC and tumour thrombus. Those patients with a preoperative NLR above 4 had significantly shorter median overall survival (OS) than those with an NLR of 4 or below (15.2 vs 24.7 months).

Read more in Renal & Urology News here